Clinical Trials Browser

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis

NCT02062359 2016-06-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Phase 2 Terminated

2 enrolled 7 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00743509 2015-09-28

OCR

Phase 2 Completed

49 enrolled 7 charts

Sarcoma

Neoplasm Metastasis, Recurrence, Sarcoma, Osteosarcoma

NCT01067989 2015-07-08

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Phase 2 Terminated

22 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00001832 2012-12-21

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase 2 Completed

170 enrolled 23 charts

BreastDermatologic

Breast Neoplasms, Melanoma, Neoplasm Metastasis

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Phase 2 Completed

12 enrolled 10 charts

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Clinical Trials

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Triple-B

REPROGRAM-01

A Phase 2 Trial for Patients With Metastatic Solid Cancer

METEORA-II

TONIC

CHEMOIMMUNE

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

GLATO2017

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

OCR

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes